4.4 Review

Factors Associated with Survival From Xp11.2 Translocation Renal Cell Carcinoma Diagnosis-A Systematic Review and Pooled Analysis

期刊

PATHOLOGY & ONCOLOGY RESEARCH
卷 27, 期 -, 页码 -

出版社

FRONTIERS MEDIA SA
DOI: 10.3389/pore.2021.610360

关键词

TFE3; kidney; Xp112 translocation renal cell carcinoma; survival; prognosis

资金

  1. National Natural Science Foundation of China [SQ2017YFSF090096, 81872089, 81370849, 81672551, 81572517, 81300472, 81070592, 81202268, 81202034]
  2. Natural Science Foundation of Jiangsu Province [BE2019751, BK20161434, BL2013032, BK20150642, BK2012336]
  3. Six talent peaks project in Jiangsu Province
  4. Jiangsu Provincial Medical Innovation Team [CXTDA2017025]
  5. Jiangsu Provincial Medical Talent [ZDRCA2016080]

向作者/读者索取更多资源

This study aimed to comprehensively characterize Xp11.2 tRCC patients and identify risk factors associated with overall survival (OS) and progression-free survival (PFS). T stage at presentation was found to be significantly associated with both PFS and OS, while age, T stage, and metastasis status were also identified as predictors of OS. Patients with higher T stage, older age, or metastases were shown to have poorer outcomes.
Purpose: Xp11.2 translocation renal cell carcinoma (Xp11.2 tRCC) is a rare subtype of renal cell carcinoma (RCC), characterized by translocations of Xp11.2 breakpoints, involving of the transcription factor three gene (TFE3). The aim of our study was to comprehensively characterize the clinical characteristics and outcomes, and to identify risk factors associated with OS and PFS in Xp11.2 tRCC patients. Methods: Literature search on Xp11.2 tRCC was performed using databases such as pubmed EMBASE and Web of Science. Studies were eligible if outcomes data (OS and/or PFS) were reported for patients with a histopathologically confirmed Xp11.2 tRCC. PFS and OS were evaluated using the univariable and multivariable Cox regression model. Results: There were 80 eligible publications, contributing 415 patients. In multivariable analyses, the T stage at presentation was significantly associated with PFS (HR: 3.87; 95% CI: 1.70 to 8.84; p = 0.001). The median time of PFS was 72 months. In the multivariable analyses, age at diagnosis (HR: 2.16; 95% CI: 1.03 to 4.50; p = 0.041), T stage at presentation (HR: 4.44; 95% CI: 2.16 to 9.09; p < 0.001) and metastasis status at presentation (HR: 2.67; 95% CI: 1.12 to 6.41; p = 0.027) were all associated with OS, with a median follow-up time of 198 months. Conclusion: T stage at presentation is the only factor that is associated with both PFS and OS in patients with Xp11.2 tRCC. Also, patients over 45 or with metastases are more likely to have poorer OS.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.4
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据